- The European Patent Office has issued patent to CEL-SCI (NYSE:CVM) titled “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS platform technology.
- We are in the process of completing pre-IND studies for CEL-4000, being developed against Rheumatoid Arthritis, and hope to start human studies with CEL-4000 next year. LEAPS is also currently being tested at the University of Georgia vaccine center against COVID-19,” said Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology.
- LEAPS is under development as a therapeutic vaccine for rheumatoid arthritis with support of a NIAMS grant of the National Institutes of Health.
- Shares are up 1.3% in premarket.